Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 37 Issue 1
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2019  >  37(1): 80-85

JIN Feihong, CHEN Jie, YANG Wenchao. The efficacy and safety of diterpene ginkgolides meglumine injection in stroke: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 80-85. doi: 10.3969/j.issn.1006-0111.2019.01.019
Citation: JIN Feihong, CHEN Jie, YANG Wenchao. The efficacy and safety of diterpene ginkgolides meglumine injection in stroke: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 80-85. doi: 10.3969/j.issn.1006-0111.2019.01.019
shu

The efficacy and safety of diterpene ginkgolides meglumine injection in stroke: a Meta-analysis

doi: 10.3969/j.issn.1006-0111.2019.01.019
  • 1.

    Department of Pharmacy, Traditional Chinese Medical Hospital of Zhuji, Zhuji 311800, China

  • 2.

    Department of Pharmacy, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China

  • Received Date: 2018-06-15
  • Rev Recd Date: 2018-09-04
  • Objective Diterpene ginkgolides meglumine injection (DGMI) is widely used in patients with stroke, but its efficacy and safety are not consistent. We performed a Meta-analysis to comprehensively evaluate the efficacy and safety of DGMI in acute ischemic stroke and recovered stroke. Methods The wanfang, VIP, CNKI and PubMed were searched, the randomized controlled trials (RCTs) were enrolled. Data collection and quality evaluation of the included RCTs were performed according to Cochrane systematic evaluation method. Meta-analysis was performed by using Stata software. Results 9 RCTs involving 1 129 subjects were included with 706 subjects in DGMI treatment group and 423 subjects in control group. ① For acute ischemic stroke, DGMI group had superior effective rate compared to conventional therapy group (RR=1.19, 95%CI:1.09, 1.31, P<0.000 1), improvement of neurologic impairments (SMD=3.23, 95%CI:2.87, 3.60, P<0.000 1) and improvement of living quality (SMD=3.23, 95%CI:2.87, 3.60, P<0.000 1). ② For recovered stroke, DGMI group had better effective rate than Shuxuening injection group (RR=1.17, 95%CI:1.05, 1.30, P<0.05) and improvement of neurologic impairments (SMD=-0.69, 95%CI:-0.88, -0.49, P<0.000 1). There was no significant difference in adverse events between DGMI and control groups (P>0.05). Conclusion DGMI had superior efficacy over control group for both acute ischemic stroke and recovered stroke. There was no significant difference in adverse events between these two groups. However, we still need better quality RCTs to confirm these results.
  • [1] LOZANO R, NAGHAVI M, FOREMAN K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet,2012,380(9859):2095-2128.
    [2] WANG W, JIANG B, SUN H, et al. Prevalence, incidence and mortality of stroke in China clinical perspective[J]. Circulation,2017,135(8):759-771.
    [3] 王晓勇, 骆守真, 崔春丽. 银杏二萜内酯葡胺注射液治疗急性脑梗死临床研究[J]. 河北中医, 2017,39(9):1328-1331.
    [4] 李海龙, 尹晓新. 银杏二萜内酯葡胺注射液治疗急性缺血性脑卒中的临床观察[J]. 现代医院,2017,17(2):239-240.
    [5] 骆继业, 谢永鹏, 陈晓兵,等. 银杏二萜内酯葡胺注射液治疗老年急性脑梗死疗效观察[J]. 世界最新医学信息文摘,2017,17(58):16-18.
    [6] 王敏, 蔡胜男, 李迪,等. 银杏二萜内酯葡胺注射液对急性脑梗死患者神经功能的影响[J]. 中国实用神经疾病杂志,2016,19(7):29-31.
    [7] 邱斌, 肖展翅. 银杏二萜内酯葡胺注射液治疗急性脑梗死的临床观察[J]. 中西医结合心脑血管病杂志,2015,13(8):1033-1035.
    [8] 高聚, 姜华, 肖展翅,等. 银杏二萜内酯葡胺注射液治疗急性脑梗死的临床疗效观察[J]. 实用心脑肺血管病杂志, 2015,23(4):133-134.
    [9] 肖展翅, 倪小红, 李钢,等. 银杏二萜内酯葡胺注射液对脑梗死恢复期患者血液流变学的影响[J]. 中西医结合心脑血管病杂志,2015,13(16):1828-1830.
    [10] 赵宾江, 王振中, 凌娅,等. 银杏二萜内酯葡胺注射液治疗动脉粥样硬化性血栓性脑梗死恢复期(痰瘀阻络证)Ⅲ期临床试验[D]. 中草药,2013,44(24):3525-3530.
    [11] 华玉凡. 银杏二萜内酯葡胺注射液治疗缺血性卒中恢复期(痰瘀阻络证)的临床研究[D]. 武汉:湖北中医药大学,2015.
    [12] 张雯, 宋俊科, 何国荣,等. 银杏二萜内酯对缺血/再灌注大鼠脑组织中神经递质的影响[J]. 中国药理学通报,2016,32(12):1648-1656.
    [13] WANG X, JIANG C M, WAN H Y, et al. Neuroprotection against permanent focal cerebral ischemia by ginkgolides A and B is associated with obstruction of the mitochondrial apoptotic pathway via inhibition of c-Jun N-terminal kinase in rats[J]. J Neurosci Res, 2014,92(2):232-242.
    [14] GU J H, GE J B, LI M, et al. Inhibition of NF-kappaB activation is associated with anti-inflammatory and anti-apoptotic effects of Ginkgolide B in a mouse model of cerebral ischemia/reperfusion injury[J]. Eur J Pharmac Sci,2012,47(4):652-660.
    [15] MA S, YIN H, CHEN L, et al. Neuroprotective effect of ginkgolide K against acute ischemic stroke on middle cerebral ischemia occlusion in rats[J]. J Nat Med,2012,66(1):25-31.
  • 加载中
通讯作者: 陈斌, [email protected]
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(4727) PDF downloads(434) Cited by()

Related
Proportional views

The efficacy and safety of diterpene ginkgolides meglumine injection in stroke: a Meta-analysis

doi: 10.3969/j.issn.1006-0111.2019.01.019
  • 1. Department of Pharmacy, Traditional Chinese Medical Hospital of Zhuji, Zhuji 311800, China
  • 2. Department of Pharmacy, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China
  • Received Date: 2018-06-15
  • Rev Recd Date: 2018-09-04

Abstract: Objective Diterpene ginkgolides meglumine injection (DGMI) is widely used in patients with stroke, but its efficacy and safety are not consistent. We performed a Meta-analysis to comprehensively evaluate the efficacy and safety of DGMI in acute ischemic stroke and recovered stroke. Methods The wanfang, VIP, CNKI and PubMed were searched, the randomized controlled trials (RCTs) were enrolled. Data collection and quality evaluation of the included RCTs were performed according to Cochrane systematic evaluation method. Meta-analysis was performed by using Stata software. Results 9 RCTs involving 1 129 subjects were included with 706 subjects in DGMI treatment group and 423 subjects in control group. ① For acute ischemic stroke, DGMI group had superior effective rate compared to conventional therapy group (RR=1.19, 95%CI:1.09, 1.31, P<0.000 1), improvement of neurologic impairments (SMD=3.23, 95%CI:2.87, 3.60, P<0.000 1) and improvement of living quality (SMD=3.23, 95%CI:2.87, 3.60, P<0.000 1). ② For recovered stroke, DGMI group had better effective rate than Shuxuening injection group (RR=1.17, 95%CI:1.05, 1.30, P<0.05) and improvement of neurologic impairments (SMD=-0.69, 95%CI:-0.88, -0.49, P<0.000 1). There was no significant difference in adverse events between DGMI and control groups (P>0.05). Conclusion DGMI had superior efficacy over control group for both acute ischemic stroke and recovered stroke. There was no significant difference in adverse events between these two groups. However, we still need better quality RCTs to confirm these results.

JIN Feihong, CHEN Jie, YANG Wenchao. The efficacy and safety of diterpene ginkgolides meglumine injection in stroke: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 80-85. doi: 10.3969/j.issn.1006-0111.2019.01.019
Citation: JIN Feihong, CHEN Jie, YANG Wenchao. The efficacy and safety of diterpene ginkgolides meglumine injection in stroke: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 80-85. doi: 10.3969/j.issn.1006-0111.2019.01.019
shu

    HTML

Reference (15)

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return